AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol (October 5, 2007). doi:10.1152/ajpheart.00646.2007
This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/1/H145    most recent
00646.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hong, T.-T.
Right arrow Articles by Lucchesi, B. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hong, T.-T.
Right arrow Articles by Lucchesi, B. R.
Submitted on June 5, 2007
Accepted on October 3, 2007

Effects of Cyclooxygenase Inhibition on Canine Coronary Artery Blood Flow and Thrombosis

Ting-Ting Hong1, Jinbao Huang1, Terrance D. Barrett2, and Benedict R. Lucchesi1*

1 Pharmacology, University of Michigan Medical School, Ann Arbor, Michigan, United States
2 Physiological Systems, Johnson and Johnson Pharmaceutical Research and Development, San Diego, California, United States

* To whom correspondence should be addressed. E-mail: benluc{at}umich.edu.

This study was designed to determine the effect of inhibitors of COX-1, COX-2 and the nonselective COX inhibitor, naproxen on, coronary vasoactivity and thrombogenicity under baseline and lipopolysaccharide-induced inflammatory conditions. We hypothesize that; endothelial COX-1 is the primary COX isoform in the canine normal coronary artery, which mediates arachidonic acid-induced vasodilatation. However, COX-2, can be induced and over-expressed by inflammatory mediators, and becomes the major local COX isoform responsible for production of antithrombotic prostaglandins during systemic inflammation. The interventions included the selective COX-1 inhibitor SC-560 (0.3 mg/kg i.v.), the selective COX-2 inhibitor nimesulide (5 mg/kg i.v.) or the nonselective COX inhibitor naproxen (3mg/kg, i.v.). The selective IP receptor antagonist, RO3244794 (RO), was used as an investigational tool to delineate the role of prostacyclin (PGI2) in modulating vascular reactivity. Arachidonic acid-induced vasodilatation of the left circumflex coronary artery was suppressed to a similar extent by each of the COX inhibitors and RO. The data suggest that AA-induced vasodilatation in the normal coronary artery is mediated by a single COX isoform, the constitutive endothelial COX-1, which is reported to be susceptible to COX-2 inhibitors. The effect of the COX inhibitors on thrombus formation was evaluated in a model of carotid artery thrombosis secondary to electrolytic-induced vessel wall injury. Pretreatment with LPS (0.5 mg/kg, i.v.) induced a systemic inflammatory response and prolonged the time to occlusive thrombus formation, which was reduced in the LPS treated animals by the administration of nimesulide. In contrast, neither SC-560 nor naproxen influenced the time to thrombosis in the animals pretreated with LPS. The data are of significance in view of reported adverse cardiovascular events observed in clinical trials involving the use of selective COX-2 inhibitors, thereby suggesting that the endothelial constitutive COX-1 and the inducible vascular COX-2 serve important functions in maintaining vascular homeostasis.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH
Visit Other APS Journals Online
Copyright © 1977 by the American Physiological Society.